Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

r its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attrib
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... Mass. (PRWEB) March 03, 2015 Cambridge ... by Semantic Web technology, today announced that it has ... Companies That Matter in Knowledge Management.’ , To ... group of colleagues, analysts and system integrators who identify ... delivery of the right information to the right people ...
(Date:3/3/2015)... March 3, 2015 Elsevier,s ... for implementing competency-based training to comply with new CMS ... is offering a new crosswalk tool to ... competency-based training for direct service workers as a means ... Services (CMS) regulations. CMS amended the regulations, ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer ... researcher and founding partner of Criogenix SA de CV ... professors who will teach the “Diplomat in Cell Therapy ... is a private company registered in the National Record ... (RENIECYT). , Camacho Alcocer will teach two-day, interactive training ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... developed a novel mouse model mimicking human preterm labor have ... it to stop the problem.   (Logo: ... online the week of Oct. 24 by PNAS ... researchers report their findings may lead to new strategies for ...
... Inc. ("DLVR") - a privately-held biotechnology company currently ... proprietary high density lipoprotein-like nanoparticle -announced today that ... bringing the total raised to $2 million in ... University Health Network (UHN) and the Ontario Institute ...
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
Cached Biology Technology:Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 2Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 3DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... N.J. - The inaugural Global Conference on Systems ... in Washington, DC, focuses on the convergence of complex ... The goal of the ... around targeted complex systems, examined by domain, each successive ...
... to rise scientists are presented with the complex challenge ... paper published in Insect Conservation and Diversity , ... challenge. Twentieth-Century global warming of approximately 0.6˚C has ... challenge facing ecologists and evolutionary biologists is to predict ...
... A major obstacle to HIV research is the virus,s ... traditional tools, like the humble lab mouse, can deliver only ... Central,s open access Journal of Biology have made ... that has key features of HIV infection without being infected ...
Cached Biology News:First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2How can scientists measure evolutionary responses to climate change? 2A reductionist approach to HIV research 2
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: